CommercialAdministrativeLow impact
08.02.08a, Rozanolixizumab-noli (Rystiggo)
Independence Blue Cross·Neurology, Rheumatology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
A policy for Rozanolixizumab-noli (Rystiggo), a specialty pharmacy medication, has been reissued with an effective date of May 28, 2025. This appears to be an administrative reissue of an existing commercial insurance policy rather than a substantive change to coverage or billing requirements.
Action Required
By May 28, 2025: Billing team should review the updated policy details at the provided URL to confirm any changes to prior authorization, coverage criteria, or billing requirements for Rozanolixizumab-noli (Rystiggo). This medication is typically used for specialized conditions and may require prior authorization.